Menu
Recruiting NCT05407168

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

No phase Interventional Lung Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Best Practice, Health Promotion and Education, Questionnaire Administration.
Who it may be relevant to
Registry conditions: Lung Carcinoma. Basic parameters: 18 years — 99 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool

Overview

This clinical trial evaluates the effectiveness of a conversation tool on patient-centered health and decision-making outcomes in patients with lung cancer making treatment decisions. This research is being conducted to help doctors understand the information patients need to participate in shared decision-making about their lung cancer treatment options. The focus of this research is to study how patients choose lung cancer treatment options and the information needed to make that choice, with a focus on patients with lower health literacy.

Detailed description

PRIMARY OBJECTIVES:

I. Conduct a randomized, controlled trial evaluating the efficacy of a conversation tool on patient-centered health and decision-making outcomes among patients making lung cancer treatment decisions. A subset of participants from control and intervention groups will also have their clinic conversations with providers recorded II. Conduct in-depth, semi-structured qualitative audio or video recorded interviews among a subset of Aim 1 participants.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients review decision aid.

GROUP II: Patients receive standard of care.

After completion of study intervention, patients are followed up at 2 weeks, 3 months, and 6 months.

Interventions

  • Other Best Practice
    Receive standard of care
  • Other Health Promotion and Education
    View decision aid
  • Other Questionnaire Administration
    Ancillary studies

Primary outcome measures

  • Decision Conflict [Time frame: Up to 6 months]
  • Efficacy of a conversation tool on patients' knowledge of lung cancer [Time frame: Up 6 months]
  • Satisfaction with Communication/Confidence in Decision [Time frame: Up to 6 months]
  • Self-Efficacy [Time frame: Up to 6 months]
Secondary outcome measures (8)
  • FACT-L [Time frame: Up to 6 months.]
  • Depression/Anxiety [Time frame: Up to 6 months]
  • Participation in Decision-Making [Time frame: Up to 6 months]
  • Decision Regret [Time frame: Up to 6 months]
  • Quality of Communication [Time frame: Up to 6 months]
  • Number of Palliative Care Referrals [Time frame: Up to 6 months]
  • Treatment Decision-Making Concordance [Time frame: Up to 6 months]
  • Acceptability [Time frame: Up to 6 months]

Eligibility criteria

Inclusion criteria

  • AIM 1: Suspected lung cancer
  • AIM 1: English fluency
  • AIM 1: > 6-month life expectancy
  • AIM 1: Score of ≥ 3 on the cognitive impairment screener
  • AIM 2 PARTICIPANTS: Participation in Aim 1
  • AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Health services research

Study locations

United States · 4 centers
  • Hillsboro Medical Center — Hillsboro
  • Adventist Health Portland — Portland
  • OHSU Knight Cancer Institute — Portland
  • Portland VA Medical Center — Portland

Publications

  • Disher N, Dieckmann NF, Case JR, Rubim F, Eden KB, Golden SE, Matlock DD, Coleman C, Lyons KS, Saha S, Slatore CG, Vranas KC, Sullivan DR. Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial. Future Oncol. 2025 Apr;21(9):1045-1056. doi: 10.1080/14796694.2025.2475733. Epub 2025 Mar 18. PMID 40098532

Identifiers

NCT: NCT05407168 · STUDY00023160 · NCI-2021-09819 · STUDY00023160

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗